Introduction: Clinical efficacy of everolimus, an allosteric TORC1-selective inhibitor, has been established in pancreatic NET. CC-223 is an ATP-competitive inhibitor of the mTOR kinase, inhibiting both TORC1 and TORC2.
Aim(s): To evaluate clinical activity of CC-223 in NET.
Materials and methods: After establishing MTD, subjects with non-pancreatic NET on somatostatin analogues (SSA) and progressing within 12 months were enrolled in an expansion cohort of CC-223 at 45mg QD in 28-day cycles.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Professor Tim Meyer
To read results and conclusion, please login ...
Further abstracts you may be interested in